When a woman with blood group D- is pregnant with a child with blood group D+, the mother’s immune system can be activated, resulting in the production of antibodies. These antibodies can enter the child’s bloodstream before or during birth, attacking their red blood cells. This condition is called hemolytic disease of the fetus and newborn and children affected are known as Rhesus babies. To prevent these adverse effects, pregnant women with D- are now given an antenatal injection of Rh prophylaxis, also known as anti-D. It is produced from the plasma of hyperimmunized anti-D donors and is therefore in limited supply. Tamara Stegmann’s research focuses on experimental models for studying the working mechanisms of anti-D, so effective recombinant antibodies can be developed that can be used as an alternative source.